Analyst
Canopy Growth // amazing Risk-Reward
There is a critical support range from $20-25
Risk-Reward-Ratio above > 5:1 .
Analyst note:
Shares now trade nearly 50% below our fair value estimate, as the lack of profitability continues to weigh
on the market price. However, we think focusing on profitability this early in the company’s and industry’s
evolution is misguided.
Davita - now a BULL trend Technicals analysis WEEKLY
Davita broke a downtrend channel, and is now in a consolidation above the 200SMA. (Bull)
50SMA is now crossing above the 200SMA. (Bull)
OBV and RSI show divergence, as they have moved in oposite directions since early August. (Short). However... on a daily chart , we see a decent uptrend since early June.
Headlines / Fundamental
On July 10th:
President Donald Trump on Wednesday signed an executive order reimbursing for kidney transplants and reducing the reliance on the costly treatments at dialysis clinics.
Analyst fair value target price is $79. Meaning 38% undervalued .
Will they name JCPenney JCPenny?J. C. Penney Company, Inc. is an American department store chain with 865 locations. It is a micro-cap @$187million.
This upcoming earnings, this companies fate will be decided as the street awaits details of long-term plan.
If the stock remains below $1 for a period of 30 consecutive business days, they will face delisting from the NYSE market.
JCP August 0.50 straddle is priced for a move of 30% into the expected release of quarterly results before the bell on August 15th.
Analyst note:
B. Riley FBR lowers their JCP target to $0.60 from $1.30 as they believe that amid traffic/discounting pressure that has been impacting retail in general, there is downside risk to estimates.
Alibaba - don't miss this train!Technicals
There has been no divergence with RSI and the OBV and trade price. They are steadily growing. ----> BULL
DI+>DI- (positive directional index just crossed above the negative) ---> BULL
MACD>MACsignal (MACD just crossed above the signal) -----> BULL
Fundamentals
Alibaba reported earnings yesterday (Aug15th) continued positive non-GAAP earnings of $1.84 per share, 45.98% above the same quarter a year ago, beating the mean consensus estimate of $1.51.
All analyst price target values are above $200 (17% above current price @$170)
Risks
JD.com who is a competitor, is doing great.
Trade war between China & USA.
G1 Therapeutics RALLYEarnings/News
Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions
GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September
FDA's move is a recognition that clinical data presented so far reflects the potential for trilaciclib to address an urgent unmet medical need - Cowen & Co
Analyst Actions
JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38
Moog Strong Pullback Fundamental analysis
MOG.A dropped 15% in 2 days, after beating earnings, revenue, and reaffirms FY19 EPS guidance.
Analyst lowered price target from $102 to $92
Technical analysis
OBV did not fall below it's high since late June.
RSI(10) @30.5, not wanting to go into oversold territory.
*Note:
If the stock market rallies tomorrow with the fed announcement to cut rates. This stock will probably too.
BABA is cheap - below all analysts targetsTechnical analysis (daily chart)
RSI(10) @62
OBV on steady uptrend along with the RSI
CCI(10) @100
MACD > MACDsignal
Fundamental analysis
BABA is a buy right now @$177. Well below analyst price average targets of $225. (Over 25%)
Fair value Morningstar note
Our fair value estimate is $240 per ADS incorporates management's full-year fiscal 2020 outlook calling for over CNY 500 billion in revenue (representing 33% growth year over year).
* Meaning... If they achieve this growth, the price target will make sense.
Good luck!
dorfmanmaster
BUD technicals and fundamentals look greatFundamentals
Analysts are pricing BUD @$118 (24% above current price!)
New products and hype.
Technicals
OBV has been increasing steadily. But on a longer term, you can see the average volume is now lower than previous years.
BUD is breaking above a weekly resistance 50SMA.
BMRN ridiculous Morningstar analyst target price! Morningstar weekly highlights set Biomarin Pharmaceuticals with an amazing $119 fair price value ( 50% above current price).
Rating: 4 stars
Uncertainty rating: Medium
Moat: Narrow
CrowdStrike 1st time earnings Another of the IPO's I really like this year is CRWD, they will report earnings for the first time this Thursday.
Most analysts have a buy rating, with a price target 90$-100$. Meaning 12.5%-25% potential upside.
ZOOM - Bullish analyst ratingOne of this year's hottest IPOs is still winning over new fans. Dmitry Netis at Stephens is initiating coverage of Zoom Video (ZM) with a bullish overweight rating .
The analyst's price target of $115 suggests that there's 26% of upside from current levels, an encouraging goal for the provider of video-conferencing solutions for enterprises that has already soared 153% since going public at $36 in April through Thursday's close.
---News reported by Rick Munarriz, The Motley Fool / Yahoo Finance
Black Hills Corporation uptrendBlack Hills Corporation has established an uptrend and sung down near the bottom of its channel in the last few days. This offers a buying opportunity.
It's finding some support at June 20 lows of 79.44. It should move above that level by the end of the week. It next reports earnings August 5 and pays a dividend on August 15.
ONT \ BTC NextmovePossible movement of ONT \ BTC next month
Black line was support at 4600 and 4550 in april 2018 and became strong resistance from august 2018 at 4200, 4100, 4000, 3300, 3250
Green line, was support at 2000 and 1500 sat on march 2018 and return support from december 2018 to february 2019
ONT is in trend channel from 2000 (support) to 2500 (resistance), we are watch possible new channel (yellow one)
IF ONT broke upper resistance can push up to black line (strong resistance) in area 3000 sat
IF ONT broke lower support return to 1500 sat.
What we expect (it's a personal vision, not a suggestion) PURPLE LINE
Eyes on Euro. Hello traders, i am expecting euro to gain strength from that purple box. Also EUR/USD drops to test last week lows near 1.1200.
Its a good entry point to buy for both pairs. Hoping another good week of trading. Control your emotions, and always use the correct risk management. bless !
$EEMS LIKE A DECENT BUY ON GA AYYE GOOD RISK REWARD POSTING THIS ABIT LATE AUSSIE NEWS AT TIME OF THIS . NICE SWING UP .. HOPEFULLY WITH SOME FORCE :) ENJOI
"Risk Management" (Traders) vs "Right or Wrong" (Analysts)In this video I explain you with a real time trading context, what the major difference is between a trader and an analyst. Because that's how you'll easily make the difference between the one that actually trade and manage its risks, and the one that just talks and do nothing ! Always remember that if you want to learn how to analyse a market, the follow analysts ! If you want to learn how to trade and manage the risks, follow traders... ! Because being right or wrong is nothing but bullshit in a speculative prospective !
Bests,
Phil
MA's and Slingshot giving beautiful short signal on SPXI recently started studying the Slingshot system by chrismoody and find it super relevant so far. In the chart above we have an aggressive sell setup coupled with a bump into some simple MA resistance. On top of that this lovely opportunity comes after a somewhat exhaustible run up since first week of November 2019 making a small correction all the more feasible. My target over the next 2 - 4 days is 2512 - 2550.
Gold Potential (Adam & Adam)Gold has reached its resistance 1303 and will correct again to the yellow box area.
ZRX/BTC When global support breaks through in a triangle, go to 5000 sat. Stoop-loss at 8000 - 8200 sat. Volumes are large, but can be seen in the shadow of the candle that buy at this level, while good support.
